Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00004772

Recruitment Status : Completed

First Posted : February 25, 2000

Last Update Posted : June 24, 2005

Sponsor:

Collaborator:

Ohio State University

Information provided by:

Office of Rare Diseases (ORD)

Study Description

Brief Summary:

OBJECTIVES:

I. Compare the response of previously untreated patients with chronic inflammatory demyelinating polyneuropathy to intravenous immune globulin vs. placebo.

Condition or disease	Intervention/treatment	Phase
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	Drug: Immune globulin	Phase 3

Detailed Description:

PROTOCOL OUTLINE: This is a randomized, double-blind study. The first group receives intravenous immune globulin (IVIG) on days 1, 2, and 21; the second group receives an intravenous placebo on the same schedule.

Patients in either group may receive IVIG (same dosage as first group) after day 42.

Concurrent steroids and other immune globulin preparations are prohibited.

Study Design


Study Type :	Interventional (Clinical Trial)
Enrollment :	90 participants
Allocation:	Randomized
Masking:	Double
Primary Purpose:	Treatment
Study Start Date :	September 1992

Resource links provided by the National Library of Medicine

Drug Information available for: Globulin, Immune Rhophylac

Genetic and Rare Diseases Information Center resources: Chronic Inflammatory Demyelinating Polyneuropathy

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	15 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Chronic inflammatory demyelinating polyneuropathy (CIDP), i.e.: Progressive or relapsing motor and sensory dysfunction of more than 1 limb over at least 2 months Hypo- or areflexia of at least 2 limbs No myelopathy No central demyelination No drug or toxic exposure known to cause peripheral neuropathy --Prior/Concurrent Therapy-- No prior corticosteroids or other immunomodulators for CIDP No prior plasmapheresis At least 30 days since participation in other investigational study At least 6 months since the following: Cyclophosphamide Intravenous immune globulin Cyclosporine Interferon alfa Azathioprine Corticosteroids Orthoclone Tacrolimus --Patient Characteristics-- Hepatic: No hepatitis Renal: Not specified Neurologic: Cerebrospinal fluid (CSF) protein greater than 50 mg/dL CSF cell count less than 10 CSF VDRL negative 3 of the following motor abnormalities by electrophysiology: Reduced conduction velocity in 2 or more motor nerves Less than 80% of normal if amplitude greater than 80% of normal Less than 70% of normal if amplitude less than 80% of normal Conduction block or abnormal temporal dispersion in 1 motor nerve No ulnar or peroneal nerve entrapment Prolonged distal latency in 2 or more nerves Greater than 125% of normal if amplitude greater than 80% of normal Greater than 150% of normal if amplitude less than 80% of normal Absent F-waves or H response (patients aged under 60) or prolonged shortest F-wave latency in 10 to 15 trials in 2 or more motor nerves Other: No hypersensitivity to immune globulin No IgA deficiency No mutilation of hands or feet No retinitis pigmentosa No ichthyosis No disease that would limit neuromuscular assessment No endocrinopathy No connective tissue disease or vasculitis No Lyme disease No malignancy No Castleman's disease No hyper- or hypothyroidism No HIV infection No alcohol or drug abuse No pregnant or nursing women

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004772

Sponsors and Collaborators

National Center for Research Resources (NCRR)

Ohio State University

Investigators


Study Chair:	Jerry R. Mendell	Ohio State University

More Information


ClinicalTrials.gov Identifier:	NCT00004772 History of Changes
Other Study ID Numbers:	199/11794 OSU-92H0250
First Posted:	February 25, 2000 Key Record Dates
Last Update Posted:	June 24, 2005
Last Verified:	December 2001

Keywords provided by Office of Rare Diseases (ORD):


demyelinating neuropathy neurologic and psychiatric disorders rare disease

Additional relevant MeSH terms:


Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Demyelinating Diseases Polyneuropathies Polyradiculoneuropathy Autoimmune Diseases of the Nervous System Nervous System Diseases Peripheral Nervous System Diseases Neuromuscular Diseases Autoimmune Diseases	Immune System Diseases Immunoglobulins Antibodies gamma-Globulins Immunoglobulins, Intravenous Rho(D) Immune Globulin Immunologic Factors Physiological Effects of Drugs

To Top